JPMorgan Chase & Co. Boosts Mobia Medical (NASDAQ:MOBI) Price Target to $17.00

Mobia Medical (NASDAQ:MOBI) had its price target raised by stock analysts at JPMorgan Chase & Co. from $15.00 to $17.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 35.24% from the stock’s previous close.

Other research analysts have also recently issued research reports about the stock. The Goldman Sachs Group started coverage on shares of Mobia Medical in a research report on Tuesday, June 2nd. They set a “buy” rating and a $31.00 price target on the stock. Wolfe Research initiated coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They set an “outperform” rating on the stock. BTIG Research reiterated a “buy” rating and issued a $19.00 target price on shares of Mobia Medical in a report on Wednesday. Bank of America started coverage on Mobia Medical in a research report on Tuesday, June 2nd. They issued a “buy” rating and a $16.00 price objective for the company. Finally, Zacks Research raised Mobia Medical to a “hold” rating in a research note on Wednesday, June 3rd. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $20.75.

Mobia Medical Stock Performance

MOBI traded down $0.01 on Wednesday, hitting $12.57. 29,325 shares of the company’s stock were exchanged, compared to its average volume of 145,131. Mobia Medical has a fifty-two week low of $10.19 and a fifty-two week high of $15.29. The company has a market capitalization of $417.94 million and a PE ratio of -0.65. The firm’s 50-day simple moving average is $12.54.

Mobia Medical (NASDAQ:MOBI) last released its earnings results on Tuesday, August 11th. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The business had revenue of $13.51 million for the quarter. The firm’s revenue was up 102.4% compared to the same quarter last year. As a group, equities research analysts forecast that Mobia Medical will post -2.5 EPS for the current fiscal year.

Insider Transactions at Mobia Medical

In other news, CFO Nelson Bunker Curnes purchased 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 9th. The stock was bought at an average price of $12.79 per share, for a total transaction of $63,950.00. Following the completion of the purchase, the chief financial officer directly owned 366,997 shares of the company’s stock, valued at $4,693,891.63. The trade was a 1.38% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Key Stories Impacting Mobia Medical

Here are the key news stories impacting Mobia Medical this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating and set a $19.00 price target, implying substantial upside from the recent trading level. The endorsement reflects confidence in Mobia Medical’s growth prospects. Benzinga analyst rating report
• Positive Sentiment: Second-quarter revenue rose 102.4% year over year to $13.51 million, while gross margin reached 83.2%. Management also forecast 2026 revenue of $54 million to $56 million, above the approximately $53.5 million analyst consensus, representing expected growth of roughly 69% to 75%. Mobia Medical second-quarter 2026 financial results
• Positive Sentiment: Mobia Medical highlighted two-year VNS-REHAB follow-up data showing durable improvements in upper-limb motor function, daily living activities and quality of life. The company also completed its IPO, raising approximately $134 million in net proceeds, strengthening its funding position. Clinical data and IPO highlights
• Neutral Sentiment: The IPO proceeds and continued commercialization could support expansion, but investors will likely focus on how quickly the company converts revenue growth into profitability.
• Negative Sentiment: Mobia Medical reported a second-quarter loss of $1.10 per share, wider than the analyst consensus loss of $0.83 per share. The company remains unprofitable, with analysts expecting a full-year loss of approximately $2.50 per share, creating pressure despite strong sales growth. Mobia Medical earnings report

About Mobia Medical

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.